Autolus Therapeutics (NASDAQ:AUTL) Shares Down 3.6%

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report)'s share price traded down 3.6% on Monday . The stock traded as low as $5.26 and last traded at $5.40. 447,679 shares traded hands during mid-day trading, a decline of 71% from the average session volume of 1,568,210 shares. The stock had previously closed at $5.60.

Analyst Upgrades and Downgrades

Several research firms have recently commented on AUTL. Needham & Company LLC restated a "buy" rating and set a $9.00 price target on shares of Autolus Therapeutics in a research report on Thursday, March 14th. Truist Financial lifted their target price on Autolus Therapeutics from $9.00 to $10.00 and gave the company a "buy" rating in a research report on Monday, March 18th. Finally, The Goldman Sachs Group increased their price target on shares of Autolus Therapeutics from $3.20 to $4.80 and gave the stock a "neutral" rating in a research report on Wednesday, December 13th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, Autolus Therapeutics has an average rating of "Moderate Buy" and an average target price of $7.96.

Autolus Therapeutics Trading Down 3.0 %

The company has a market cap of $1.44 billion, a PE ratio of -4.56 and a beta of 1.90. The company has a fifty day simple moving average of $6.10 and a two-hundred day simple moving average of $4.97.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its earnings results on Thursday, March 14th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.18). On average, research analysts anticipate that Autolus Therapeutics plc will post -0.73 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Cetera Investment Advisers raised its position in shares of Autolus Therapeutics by 8.3% during the 1st quarter. Cetera Investment Advisers now owns 124,300 shares of the company's stock worth $518,000 after acquiring an additional 9,550 shares in the last quarter. Nantahala Capital Management LLC lifted its position in shares of Autolus Therapeutics by 6.6% during the 1st quarter. Nantahala Capital Management LLC now owns 4,346,327 shares of the company's stock worth $18,124,000 after buying an additional 268,818 shares during the last quarter. UBS Group AG lifted its position in shares of Autolus Therapeutics by 716.1% during the 1st quarter. UBS Group AG now owns 73,858 shares of the company's stock worth $308,000 after buying an additional 64,808 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Autolus Therapeutics by 144.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 375,514 shares of the company's stock valued at $1,566,000 after buying an additional 222,093 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in shares of Autolus Therapeutics in the 2nd quarter valued at $36,000. 72.83% of the stock is currently owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.